Zomedica (OTC:ZOMDF) versus Endonovo Therapeutics (OTCMKTS:ENDVD) Head-To-Head Review

Institutional & Insider Ownership

8.9% of Zomedica shares are held by institutional investors. 5.6% of Zomedica shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Zomedica and Endonovo Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zomedica	N/A	N/A	N/A	($0.10)	-1.32
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A

Zomedica has higher earnings, but lower revenue than Endonovo Therapeutics. Zomedica is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zomedica and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zomedica	N/A	N/A	N/A
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Volatility and Risk

Zomedica has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.